出血性脳卒中の世界市場2019-2023

◆英語タイトル:Global Hemorrhagic Stroke Treatment Market 2019-2023
◆商品コード:IRTNTR30243
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年11月21日
◆ページ数:113
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、出血性脳卒中の世界市場について調査・分析し、市場概要、市場環境、出血性脳卒中市場規模、製品別(抗高血圧症治療薬、抗凝固剤、利尿剤、抗痙攣剤)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・出血性脳卒中の世界市場概要
・出血性脳卒中の世界市場環境
・出血性脳卒中の世界市場動向
・出血性脳卒中の世界市場規模
・出血性脳卒中の世界市場:業界構造分析
・出血性脳卒中の世界市場:製品別(抗高血圧症治療薬、抗凝固剤、利尿剤、抗痙攣剤)
・出血性脳卒中の世界市場:地域別市場規模・分析
・出血性脳卒中の北米市場規模・予測
・出血性脳卒中のヨーロッパ・中東・アフリカ市場規模・予測
・出血性脳卒中のアジア太平洋市場規模・予測
・出血性脳卒中の主要国分析
・出血性脳卒中の世界市場:意思決定フレームワーク
・出血性脳卒中の世界市場:成長要因、課題
・出血性脳卒中の世界市場:競争環境
・出血性脳卒中の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、Baxter、Novartis、Pfizer、Sanofiなどです。
【レポートの概要】

About this market
The improved diagnostic modalities for hemorrhagic stroke recovery to help market grow. For the appropriate management of hemorrhagic stroke, an adequate understanding of parenchymal hemorrhage is crucial. Since intracerebral hemorrhage is an acute clinical manifestation of the underlying cerebral small vessel diseases (cSVDs), it is essential to use improved diagnostic modalities such as MRI markers to monitor the risk stratification. Technavio’s analysts have predicted that the hemorrhagic stroke treatment market will register a CAGR of almost 4% by 2023.
Market Overview
Rising incidence in aging population
Increasing age is a major risk for several conditions, including intracerebral hemorrhages. This increases the demand for drugs thereby pushing growth in the hemorrhagic stroke treatment market.
High generic influx
The patent expiry of most of the products has paved the way for the entry of generics into the market. The excessive use of generic medicine can impede the demand for branded drugs, thereby affecting the market.
For the detailed list of factors that will drive and challenge the growth of the hemorrhagic stroke treatment market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Baxter and Novartis the competitive environment is quite intense. Factors such as the improved diagnostic modalities for hemorrhagic stroke recovery and the rising incidence in aging population, will provide considerable growth opportunities to hemorrhagic stroke treatment manufactures. Baxter, Novartis, Sanofi, and Pfizer are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.’

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Antihypertensives – Market size and forecast 2018-2023
• Anticoagulants – Market size and forecast 2018-2023
• Diuretics – Market size and forecast 2018-2023
• Anticonvulsants and others – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Baxter
• Novartis
• Pfizer
• Sanofi
PART 16: APPENDIX
• Research methodology
• List of abbreviations

Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for hemorrhagic stroke treatment
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antihypertensives – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antihypertensives – Year-over-year growth 2019-2023 (%)
Exhibit 22: Anticoagulants – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Anticoagulants – Year-over-year growth 2019-2023 (%)
Exhibit 24: Diuretics – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Diuretics – Year-over-year growth 2019-2023 (%)
Exhibit 26: Anticonvulsants and others – Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Anticonvulsants and others – Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 34: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 36: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Interventions for improving drug delivery to BBB
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Baxter – Vendor overview
Exhibit 48: Baxter – Business segments
Exhibit 49: Baxter – Organizational developments
Exhibit 50: Baxter – Geographic focus
Exhibit 51: Baxter – Key offerings
Exhibit 52: Novartis – Vendor overview
Exhibit 53: Novartis – Business segments
Exhibit 54: Novartis – Organizational developments
Exhibit 55: Novartis – Geographic focus
Exhibit 56: Novartis – Segment focus
Exhibit 57: Novartis – Key offerings
Exhibit 58: Pfizer – Vendor overview
Exhibit 59: Pfizer – Business segments
Exhibit 60: Pfizer – Organizational developments
Exhibit 61: Pfizer – Geographic focus
Exhibit 62: Pfizer – Segment focus
Exhibit 63: Pfizer – Key offerings
Exhibit 64: Sanofi – Vendor overview
Exhibit 65: Sanofi – Business segments
Exhibit 66: Sanofi – Organizational developments
Exhibit 67: Sanofi – Segment focus
Exhibit 68: Sanofi – Segment focus
Exhibit 69: Sanofi – Key offerings



【掲載企業】

Baxter、Novartis、Pfizer、Sanofi

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[出血性脳卒中の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆